Drug Master File system of China (Part 2)

2024/07/04 Regulation

Medical Devices

Li Chen

Chapter 2 How to file DMF in China?

I have introduced something about the background, basic requirements of China DMF system in the previous article. This time, I am going to introduce the detail filing process.

1 DMF Filling Process
The DMF filing process for APIs, Excipients, and Packaging materials is essentially the same for all three. Based on current regulatory requirements, once the application documents are prepared, the applicant should create a report CD to be submitted to the CDE. The CDE will conduct an integrity review of the application documents. If the review is successful, the CDE will issue an acceptance notification. Otherwise, the CDE will issue a notice of supplementary to the applicant, who must address the required corrections, submit to CDE again, and then receive an acceptance notification from the CDE. The process is presented in below Figure 1.

2 DMF Technical Review Process
2.1 DMF Technical Review for APIs
After DMF filling of the APIs used in generic drugs or imported approved drug product, APIs can undergo either a Bundling Review process or a stand-alone review process. The registration status identifier for those that have been approved is “A,” while those that have not passed it are marked as “I”. Technical review processes for APIs are presented in Figure 2 and Figure 3. 

Figure 2 Technical Review Process for APIs (Bundling Review)
Figure 3 Technical Review Process for APIs (Stand-alone Review)

2.2 DMF Technical Review for Excipients/Package materials
Similar as the bundling review of APIs, the technical review process of excipients and packaging materials is shown in Figure 4.

Figure 4 Technical Review Process for Excipients and Packaging Materials

3 China DMF Maintenance
The maintenance of DMF mainly includes the following three forms: supplementary applications, annual reports, and renewal applications. Among them, the supplementary applications and re-registration mainly relate to APIs, while annual reports are applicable to all categories of DMF filings. Considering the complex categories involved in supplementary applications for APIs, those contents will not be provided in detailed. A summary of several maintenance methods is shown in below Table 3.

Table 3 Summary of DMF Maintenance
Note:
1)   For APIs marked as “A” undergoing technological changes, changes should be submitted in accordance with the relevant regulations of current drug registration regulations and implemented after approval.
2)   Minor changes to APIs, changes in Excipients and Packaging materials should be promptly updated on the registration platform and summarized related information in the annual report submitted in the 1st quarter of each year of the previous year.
3)   The regulations of APIs in China still follow the drug approval administration. Therefore, the expiration of the drug approval number for APIs is 5 years. Upon expiration, renewal approval is required. The holder of APIs should apply for renewal application to the NMPA 6 months before the expiration of the approval notice for APIs. If the review is approved, a renewal approval notice will be issued; if the review is not approved, a non-approval notice will be issued.
 

4 Prospects
The review system connecting APIs, excipients, and packaging materials has been an important part of the reform of China’s drug review and approval system since 2015. Through the active exploration and joint efforts of regulatory authorities and the industry in recent years, a relatively complete DMF system related to drugs has been established. At the same time, there is an expectation of further regulatory optimization. For example, further optimization is needed for the protection measures of core confidential control documents of intermediates, intermediate platform technologies, and upstream intermediates of biological products. The risk-based management concept for Excipients and Packaging materials, such as broader exemption measures for the DMF filling of long-term use and safety-approved pharmaceutical excipients, awaits further optimization.

 

 

About Author

Li Chen

Career

 

Global CR Med China, General Manager
 

・ Graduated from Shenyang Pharmaceutical University in 2008. After working in regulatory affairs and business development at EPS, Astellas, Asahi Kasei, dMed-Clinipac, and Redbud Medicine, he founded Global CR Med in 2023.

・ With 16 years of pharmaceutical industry experience, familiar with the regulatory and technical requirements for drug development and registration in China. Specialized in regulatory affairs and business development.

・ Involved in over 100 regulatory-related projects across therapeutic areas such as oncology, hematology, endocrinology, pain management, immunology, nephrology/urology, dermatology, inflammatory diseases, and ophthalmology.

・ Involved in the development of many imported products in China, including Enzalutamide Soft Capsules (XTANDI®), Gilteritibib (XOSPATA®) Tablets, Naftopidil (Flivas®) Tablets, Febuxostat Tablets (Feburic®), Loxoprofen Sodium Patches/Paps, Tacrolimus Capsules, Mirabegron Sustained-release Tablets, and Mizoribine Tablets, and played a leading role in some of the projects. 

・ Obtained PMP (Certificate of Project Management professional), NPDP (Certificate of New Product Development Professional), and PRINCE2 (Projects IN Controlled Environments) qualifications.

The profile is the information as of the time of writing.

Related Articles

Comment

There are no comments yet.

Our Services

You will be navigated to the CM Plus company website.

Related Sites

CM Plus Corporation

本サイトの運営会社。ライフサイエンス産業を始めとする幅広い産業分野で、エンジニアリング、コンサルティング、教育支援、マッチングサービスを提供しています。

Internet Virtual Exhibition for Life Science Industry

iVEXL is the specialized portal site, where leading companies in the Life Science Industry exhibit and deliver a wide range of information. You can view their technologies, products, and services.

海外工場建設情報プラットフォーム

海外の工場建設をお考えですか?ベトナム、タイ、インドネシアなどアジアを中心とした各国の建設物価、賃金情報、工業団地、建設許可手続きなど、役立つ情報がここにあります。

CM Plus Group Website